NYSEAMERICAN:AST - Asterias Biotherapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.94 0.00 (0.00 %)
(As of 03/24/2019 04:00 PM ET)
Previous Close$0.9450
Today's Range$0.9450 - $0.9450
52-Week Range$0.51 - $2.05
VolumeN/A
Average Volume136,653 shs
Market Capitalization$52.60 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.

Receive AST News and Ratings via Email

Sign-up to receive the latest news and ratings for AST and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:AST
Previous SymbolNYSEMKT:AST
CUSIPN/A
CIKN/A
Phone+1-510-4563805

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$52.60 million
Next Earnings DateN/A
OptionableOptionable

Asterias Biotherapeutics (NYSEAMERICAN:AST) Frequently Asked Questions

What is Asterias Biotherapeutics' stock symbol?

Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AST."

How were Asterias Biotherapeutics' earnings last quarter?

Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) released its earnings results on Tuesday, March, 28th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.01. The biotechnology company had revenue of $1.75 million for the quarter, compared to the consensus estimate of $2.81 million. View Asterias Biotherapeutics' Earnings History.

What price target have analysts set for AST?

3 Wall Street analysts have issued 1-year target prices for Asterias Biotherapeutics' stock. Their forecasts range from $6.00 to $11.00. On average, they anticipate Asterias Biotherapeutics' share price to reach $8.50 in the next year. This suggests a possible upside of 799.5% from the stock's current price. View Analyst Price Targets for Asterias Biotherapeutics.

What is the consensus analysts' recommendation for Asterias Biotherapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Asterias Biotherapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Asterias Biotherapeutics.

What are Wall Street analysts saying about Asterias Biotherapeutics stock?

Here are some recent quotes from research analysts about Asterias Biotherapeutics stock:
  • 1. According to Zacks Investment Research, "Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company's technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. " (2/20/2019)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We use a sum-of- the-parts approach, which ascribes a $440M risk-adjusted net present value (rNPV) to the AST-OPC1 program in AST-VAC programs in NSCLC and prostate cancer." (9/5/2018)

Has Asterias Biotherapeutics been receiving favorable news coverage?

Media coverage about AST stock has trended neutral on Sunday, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Asterias Biotherapeutics earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the company's share price in the next several days.

Are investors shorting Asterias Biotherapeutics?

Asterias Biotherapeutics saw a decline in short interest in the month of February. As of February 28th, there was short interest totalling 358,893 shares, a decline of 12.4% from the February 15th total of 409,735 shares. Based on an average daily trading volume, of 59,962 shares, the days-to-cover ratio is presently 6.0 days. Currently, 1.1% of the company's stock are short sold. View Asterias Biotherapeutics' Current Options Chain.

Who are some of Asterias Biotherapeutics' key competitors?

What other stocks do shareholders of Asterias Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Asterias Biotherapeutics investors own include BioTime (BTX), Synergy Pharmaceuticals (SGYP), Geron (GERN), Amicus Therapeutics (FOLD), Gilead Sciences (GILD), Progenics Pharmaceuticals (PGNX), Amarin (AMRN), Sangamo Therapeutics (SGMO), Micron Technology (MU) and Anavex Life Sciences (AVXL).

Who are Asterias Biotherapeutics' key executives?

Asterias Biotherapeutics' management team includes the folowing people:
  • Mr. Michael H. Mulroy, CEO, Pres & Director (Age 53)
  • Dr. Edward D. Wirth III, Chief Medical Officer (Age 54)
  • Dr. Katharine E. Spink, Consultant (Age 45)
  • Mr. Stephen L. Cartt, Advisor & Director (Age 56)
  • Mr. Ryan D. Chavez, CFO & Gen. Counsel (Age 43)

Who are Asterias Biotherapeutics' major shareholders?

Asterias Biotherapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Creative Planning (0.36%) and Millennium Management LLC (0.23%). View Institutional Ownership Trends for Asterias Biotherapeutics.

Which institutional investors are selling Asterias Biotherapeutics stock?

AST stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for Asterias Biotherapeutics.

Which institutional investors are buying Asterias Biotherapeutics stock?

AST stock was bought by a variety of institutional investors in the last quarter, including Creative Planning. View Insider Buying and Selling for Asterias Biotherapeutics.

How do I buy shares of Asterias Biotherapeutics?

Shares of AST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Asterias Biotherapeutics' stock price today?

One share of AST stock can currently be purchased for approximately $0.9450.

How big of a company is Asterias Biotherapeutics?

Asterias Biotherapeutics has a market capitalization of $52.60 million.

What is Asterias Biotherapeutics' official website?

The official website for Asterias Biotherapeutics is http://asteriasbiotherapeutics.com.

How can I contact Asterias Biotherapeutics?

Asterias Biotherapeutics' mailing address is 6300 Dumbarton Cir, FREMONT, CA 94555-3644, United States. The biotechnology company can be reached via phone at +1-510-4563805.


MarketBeat Community Rating for Asterias Biotherapeutics (NYSEAMERICAN AST)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  121 (Vote Outperform)
Underperform Votes:  107 (Vote Underperform)
Total Votes:  228
MarketBeat's community ratings are surveys of what our community members think about Asterias Biotherapeutics and other stocks. Vote "Outperform" if you believe AST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AST will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel